Tags

Type your tag names separated by a space and hit enter

Combined antiproliferative activity of imatinib mesylate (STI-571) with radiation or cisplatin in vitro.
Exp Oncol. 2007 Jun; 29(2):126-31.EO

Abstract

Little is known about the interaction of novel anticancer drugs with other treatment modalities. THE AIM of this study was to examine the effect of combining imatinib mesylate (STI-571) with radiation or cisplatin on the survival of two human solid tumor cell lines - SKNMC cells derived from Ewing sarcoma and breast cancer MCF-7 cells.

METHODS

Cell proliferation was determined using the sulphorodamine B cytotoxicity assay. Cell cycle analysis was performed with flow cytometry. Apoptosis was determined using a commercial cell death ELISA plus kit. Phosphorylated AKT, which has been suggested to be involved in radiation resistance, was detected by Western blot analysis.

RESULTS

Exposure of SKNMC cells to STI-571 resulted in a dose-dependent antiproliferative effect and a decrease in phosphorylated AKT expression. There was no evidence of apoptosis. The combination of STI-571 with radiation or cisplatin had an additive antiproliferative effect in SKNMC cells (60% reduction in cell number). A similar effect was observed in human MCF-7 breast cancer cells.

CONCLUSION

STI-571 improves the outcome of cisplatin or irradiation treatment in vitro. AKT pathway may play a role in the additive effect of STI-571 and irradiation.

Authors+Show Affiliations

Felsenstein Medical Research Center, Rabin Medical Center, Beilinson Campus Petach Tikva, Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

17704745

Citation

Yerushalmi, R, et al. "Combined Antiproliferative Activity of Imatinib Mesylate (STI-571) With Radiation or Cisplatin in Vitro." Experimental Oncology, vol. 29, no. 2, 2007, pp. 126-31.
Yerushalmi R, Nordenberg J, Beery E, et al. Combined antiproliferative activity of imatinib mesylate (STI-571) with radiation or cisplatin in vitro. Exp Oncol. 2007;29(2):126-31.
Yerushalmi, R., Nordenberg, J., Beery, E., Uziel, O., Lahav, M., Luria, D., & Fenig, E. (2007). Combined antiproliferative activity of imatinib mesylate (STI-571) with radiation or cisplatin in vitro. Experimental Oncology, 29(2), 126-31.
Yerushalmi R, et al. Combined Antiproliferative Activity of Imatinib Mesylate (STI-571) With Radiation or Cisplatin in Vitro. Exp Oncol. 2007;29(2):126-31. PubMed PMID: 17704745.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Combined antiproliferative activity of imatinib mesylate (STI-571) with radiation or cisplatin in vitro. AU - Yerushalmi,R, AU - Nordenberg,J, AU - Beery,E, AU - Uziel,O, AU - Lahav,M, AU - Luria,D, AU - Fenig,E, PY - 2007/8/21/pubmed PY - 2007/9/29/medline PY - 2007/8/21/entrez SP - 126 EP - 31 JF - Experimental oncology JO - Exp. Oncol. VL - 29 IS - 2 N2 - UNLABELLED: Little is known about the interaction of novel anticancer drugs with other treatment modalities. THE AIM of this study was to examine the effect of combining imatinib mesylate (STI-571) with radiation or cisplatin on the survival of two human solid tumor cell lines - SKNMC cells derived from Ewing sarcoma and breast cancer MCF-7 cells. METHODS: Cell proliferation was determined using the sulphorodamine B cytotoxicity assay. Cell cycle analysis was performed with flow cytometry. Apoptosis was determined using a commercial cell death ELISA plus kit. Phosphorylated AKT, which has been suggested to be involved in radiation resistance, was detected by Western blot analysis. RESULTS: Exposure of SKNMC cells to STI-571 resulted in a dose-dependent antiproliferative effect and a decrease in phosphorylated AKT expression. There was no evidence of apoptosis. The combination of STI-571 with radiation or cisplatin had an additive antiproliferative effect in SKNMC cells (60% reduction in cell number). A similar effect was observed in human MCF-7 breast cancer cells. CONCLUSION: STI-571 improves the outcome of cisplatin or irradiation treatment in vitro. AKT pathway may play a role in the additive effect of STI-571 and irradiation. SN - 1812-9269 UR - https://www.unboundmedicine.com/medline/citation/17704745/Combined_antiproliferative_activity_of_imatinib_mesylate__STI_571__with_radiation_or_cisplatin_in_vitro_ L2 - https://medlineplus.gov/breastcancer.html DB - PRIME DP - Unbound Medicine ER -